Fortunately, ALKi, such as alectinib and lorlatinib (7), have demonstrated efficacy in inhibiting tumor growth and improving patient outcomes in ALK-mutant gastric cancer, offering a more effective and less toxic alternative to traditional chemotherapy. This evidence concerns the gene ALK and neoplasm.